Efficacy and safety of abiraterone acetate (AA) and low-dose prednisone (P) in Japanese patients with newly diagnosed, metastatic, hormone-naive prostate cancer (mHNPC): Subgroup analysis of LATITUDE trial.

被引：0
|
作者：
Fukasawa, Satoshi
Suzuki, Hiroyoshi
Sato, Fuminori
Hashine, Katsuyoshi
Hasumi, Hisashi
Matsumoto, Hiroaki
Tsuchiya, Tomohiro
Uemura, Hirotsugu
Oya, Mototsugu
Kanayama, Hiroomi
Kawaguchi, Kazushiro
Noguchi, Hidehisa
Enjo, Kentaro
Tran, Namphuong
Todd, Mary Beth
Fizazi, Karim
Matsubara, Nobuaki
机构：
[1] Chiba Canc Ctr Hosp, Chiba, Japan
[2] Toho Univ, Sakura Med Ctr, Sakura, Japan
[3] Oita Univ, Oita, Japan
[4] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan
[5] Yokohama City Univ, Grad Sch Med, Yokohama, Kanagawa, Japan
[6] Yamaguchi Univ, Grad Sch Med, Ube, Yamaguchi, Japan
[7] Gifu Univ, Grad Sch Med, Gifu, Japan
[8] Kinki Univ, Sch Med, Osaka, Japan
[9] Keio Univ, Sch Med, Tokyo, Japan
[10] Tokushima Univ, Grad Sch, Tokushima, Japan
[11] Janssen Pharmaceut K K, Tokyo, Japan
[12] Janssen Pharmaceut K K, Chiyoda Ku, Tokyo, Japan
[13] Janssen Res Dev, LLC, Los Angeles, CA USA
[14] Janssen Global Serv, Raritan, NJ USA
[15] Univ Paris Sud, Gustave Roussy Inst Oncol, Villejuif, France
[16] Natl Canc Ctr Hosp E, Chiba, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期
关键词：
D O I：
10.1200/JCO.2018.36.6_suppl.286
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286
引用
收藏
页数：1
相关论文
共 50 条
  • [31] ASSESSMENT OF CORTICOSTEROID (CS)-ASSOCIATED ADVERSE EVENTS (AES) WITH LONG-TERM (LT) EXPOSURE TO LOW-DOSE PREDNISONE (P) GIVEN WITH ABIRATERONE ACETATE (AA) TO METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS)
    Gomella, Leonard G.
    Chi, Kim N.
    de Bono, Johann S.
    Fizazi, Karim
    Miller, Kurt
    Rathkopf, Dana E.
    Ryan, Charles J.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pelhivanov, Nonko
    Charnas, Robert
    Todd, Mary B.
    Montgomery, Bruce
    JOURNAL OF UROLOGY, 2015, 193 (04): : E1091 - E1091
  • [32] Abiraterone acetate plus prednisolone for hormone-naive prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)
    James, N.
    Rush, H.
    Clarke, N.
    Attard, G.
    Cook, A.
    Dearnaley, D.
    Gillessen, S.
    Hoyle, A.
    Jones, R.
    Millman, R.
    Birtle, A.
    Chowdhury, S.
    Gale, J.
    Malik, Z.
    O'Sullivan, J.
    Pezaro, C.
    Sheehan, D.
    Tanguay, J.
    Parmar, M. K.
    Sydes, M. R.
    ANNALS OF ONCOLOGY, 2020, 31 : S509 - S509
  • [33] Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer
    Fizazi, Karim
    Chi, Kim N.
    de Bono, Johann S.
    Gomella, Leonard G.
    Miller, Kurt
    Rathkopf, Dana E.
    Ryan, Charles J.
    Scher, Howard I.
    Shore, Neal D.
    De Porre, Peter
    Londhe, Anil
    McGowan, Tracy
    Pelhivanov, Nonko
    Charnas, Robert
    Todd, Mary B.
    Montgomery, Bruce
    EUROPEAN UROLOGY, 2016, 70 (03) : 438 - 444
  • [34] An exploratory analysis of efficacy and safety of abiraterone acetate (AA) in black patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) without prior chemotherapy (ctx)
    Efstathiou, Eleni
    Deshpande, Hari
    George, Daniel
    Joshua, Anthony M.
    Taplin, Mary-Ellen
    Griffin, Thomas W.
    Londhe, Anil
    Todd, Mary
    Molina, Arturo
    CANCER RESEARCH, 2014, 74 (19)
  • [35] Safety of long-term (LT) treatment (tmt) of chemotherapy (chemo)-naive metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with abiraterone acetate plus prednisone (AA plus P) for ≥ 4 years (yrs)
    Carles, J.
    Davis, I.
    De Bono, J. S.
    Fizazi, K.
    Gerritsen, W.
    Rathkopf, D. E.
    Ryan, C. J.
    Saad, F.
    Steuber, T.
    Wilding, G.
    Park, Y. C.
    Charnas, R.
    De Porre, P.
    Van Poppel, H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [36] IMAAGEN trial update: Effect of abiraterone acetate and low dose prednisone on PSA and radiographic disease progression in patients with non-metastatic castration-resistant prostate cancer.
    Ryan, Charles J.
    Crawford, E. David
    Shore, Neal D.
    Underwood, Willie
    Londhe, Anil
    Black, Shawn C.
    McGowan, Tracy
    Kantoff, Philip W.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [37] Abiraterone acetate plus prednisone (AA plus P) without continuing LHRH-therapy in patients with metastatic chemotherapy: Naive castrations-resistant prostate cancer-Results from the SPARE-trial (NCT02077634).
    Ohlmann, Carsten Henning
    Ruessel, Christoph
    Zillmann, Roger
    Hellmis, Eva
    Suttmann, Henrik
    Janssen, Martin
    Marin, Jan
    Dahm, Johannes
    Huebner, Andreas
    Gleissner, Jochen
    Scheffler, Michael
    Feyerabend, Susan
    Telle, Jens
    Jaehnig, Peter
    Jaschke, Michelle
    Klier, Joerg
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [38] A hypothesis-generating exploratory analysis of efficacy and safety of abiraterone acetate (AA) in African American (Af Am) patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Efstathiou, Eleni
    Assikis, Vasily J.
    North, Scott A.
    Showel, John
    Hutson, Thomas E.
    Riggs, Stephen Boyd
    Waxman, Jonathan
    Park, Youn Choi
    Kheoh, Thian San
    Haqq, Christopher M.
    Logothetis, Christopher
    Molina, Arturo
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [39] Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy plus /- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.
    Mourey, Loic
    Boyle, Helen Jane
    Roubaud, Guilhem
    McDermott, Raymond S.
    Supiot, Stephane
    Tombal, Bertrand F.
    Flechon, Aude
    Berthold, Dominik R.
    Ronchin, Philippe
    Kacso, Gabriel
    Berdah, Jean Francois
    Calabro, Fabio
    Gravis, Gwenaelle
    Palumbo, Samuel
    Gil, Thierry
    Vie, Brigitte
    Ribault, Helene
    Fizazi, Karim
    Foulon, Stephanie
    Carles, Joan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [40] Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP)
    Frobe, Ana
    Murgic, Jure
    Rauh, Stefan
    ESMO OPEN, 2016, 1 (03)
12345